Reduced-intensity conditioning transplantation in myeloid malignancies

Current Opinion in Oncology

Volumn 21, Issue SUPPL. 1, 2009, Pages

  Storb, Rainer ^a  

^a USA   (United States)

Author keywords

Acute myelocytic leukemia; Allogeneic hematopoietic cell transplantation; Graft versus leukemia effects; Myelodysplastic syndrome; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; IDARUBICIN; LEUKOCYTE ANTIGEN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DISEASE COURSE; DONOR; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENGRAFTMENT; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; REMISSION; SHORT SURVEY; TUMOR VOLUME; WHOLE BODY RADIATION;

AGED; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 68049107379     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000357467.45843.ba     Document Type: Short Survey

References (9)

1. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865-872.
2. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23:9387-9393.
3. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105:1810-1814.
4. McClune B, Weisdorf DJ, DiPersio JF, et al. Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Transplant Research (CIBMTR) [Abstract 346]. Blood 2008; 112:135.
5. Luger S, Ringden O, Peréz WS, et al. Similar outcomes using myeloablative versus reduced-intensity and non-myeloablative allogeneic transplant preparative regimens for AML or MDS: from the Center for International Blood and Marrow Transplant Research [Abstract 348]. Blood 2008; 112:136.
6. Mohty M, Labopin M, Milpied N-J, et al. Impact of cytogenetics risk on outcome after reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA identical sibling for patients with acute myeloid leukemia (AML) in first complete remission (CR1) [Abstract 345]. Blood 2008; 112:134-135.
7. Pfeifer T, Schleuning M, Eder M, et al. Improved outcome for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with poor risk cytogenetics - result from an analysis on 172 patients receiving FLAMSA-RIC conditioning for allogeneic stem cell transplantation (SCT) [Abstract 1971]. Blood 2008; 112:68.
8. Schetelig J, Bornhauser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26:5183-5191.
9. Gyurkocza B, Storb RF, Storer B, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with de novo and secondary acute myeloid leukemia [Abstract 149]. Blood 2008; 112:61.